Skip to content

Clinical trials

Withdrawn Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Status: Withdrawn Clear all

35 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20062
20073
20082
20092
20112
20121
20131
20143
20165
20172
20181
20203
20221
20231
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Withdrawn35

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center4
Bristol-Myers Squibb3
Fred Hutchinson Cancer Center2
Masonic Cancer Center, University of Minnesota2
University of Michigan Rogel Cancer Center2
Asan Medical Center1
Baptist Health South Florida1
Bellicum Pharmaceuticals1
Bio-Path Holdings, Inc.1
Centre Hospitalier Universitaire de Nice1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive35
Leukemia, Myeloid, Acute11
Precursor Cell Lymphoblastic Leukemia-Lymphoma10
Myelodysplastic Syndromes9
Leukemia7
Hematologic Neoplasms6
Hodgkin Disease6
Leukemia, Lymphocytic, Chronic, B-Cell5
Lymphoma, Non-Hodgkin5
Multiple Myeloma5

Trials

Showing 76 to 35 of 35. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.